CTLA-4 Antisense Oligonucleotide Contributes to Enhanced Immunogenicity of an Adjuvanted Recombinant <i>Sporothrix</i> spp. Enolase Antigen. [PDF]
Momente GJ +8 more
europepmc +1 more source
ABSTRACT Immune checkpoint inhibitors (ICIs) may cause rare life‐threatening ICI‐associated diabetes mellitus. We report a 60‐year‐old Chinese male with pre‐existing type 2 diabetes who developed toripalimab‐induced diabetic ketoacidosis after 3 treatment cycles. He also had toripalimab‐related hyperthyroidism.
Lingfen Zeng, Jieming Sun
wiley +1 more source
Evaluating CTLA-4 Antibody-Antigen Binding as a Model for Targeted Immunosuppressant Delivery in Hashimoto's Thyroiditis. [PDF]
Tiruvellore V, Koegle M.
europepmc +1 more source
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
T cell-intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses. [PDF]
Gilmour C +19 more
europepmc +1 more source
Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in advanced/metastatic NSCLC: a meta-analysis based on RCTs. [PDF]
Dai T +6 more
europepmc +1 more source
Triple-Mutated HSV-1 Expressing Soluble B7-1 Plus CTLA-4 Blockade Suppresses Lymph Node Metastasis in Tongue Cancer. [PDF]
Sugauchi A +11 more
europepmc +1 more source
ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma. [PDF]
Han L +10 more
europepmc +1 more source
Investigation of the CTLA-4-CD28 Axis in Oral Squamous Cell Carcinoma. [PDF]
Feldmeier F +9 more
europepmc +1 more source

